Effect of dapagliflozin in patients with diabetes and heart failure with mildly reduced or preserved ejection fraction according to background glucose-lowering therapy: A pre-specified analysis of the DELIVER trial.
Mats Christian Højbjerg LassenJohn W OstrominskiSilvio E InzucchiBrian L ClaggettIan KulacPardeep JhundRudolf A de BoerAdrian F HernandezMikhail N KosiborodCarolyn S P LamFelipe A MartinezSanjiv J ShahAkshay S DesaiMagnus PeterssonAnna Maria LangkildeKieran F DochertyJohn J V McMurrayScott D SolomonMuthiah VaduganathanPublished in: European journal of heart failure (2024)
Dapagliflozin safely and consistently improved clinical outcomes among individuals with T2D and HF with LVEF >40% irrespective of the number and class of background GLTs, and the benefits were not influenced by concomitant metformin or insulin use. These data bolster contemporary guidelines supporting first-line SGLT2i among individuals with T2D and HF, irrespective of background GLT.
Keyphrases
- ejection fraction
- heart failure
- aortic stenosis
- acute heart failure
- type diabetes
- clinical trial
- study protocol
- electronic health record
- phase iii
- big data
- blood glucose
- atrial fibrillation
- coronary artery disease
- machine learning
- metabolic syndrome
- artificial intelligence
- deep learning
- glycemic control
- data analysis
- open label